|
|
|
|
Дата |
|---|
| 15.05.2026 |
| 14.05.2026 |
| 13.05.2026 |
| 12.05.2026 |
| 11.05.2026 |
| 08.05.2026 |
| 07.05.2026 |
| 06.05.2026 |
| 05.05.2026 |
| 04.05.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
3.93
|
4.05
|
3.895
|
3.7848
|
4.07
|
4.05
|
|
|
117 685.92
|
215.00
|
|
3.88
|
4.02
|
4.03
|
3.77
|
4.10
|
4.02
|
|
|
82 094.43
|
212.00
|
|
3.71
|
4.17
|
3.845
|
3.71
|
4.07
|
4.01
|
|
|
158 575.75
|
460.00
|
|
3.71
|
4.10
|
3.81
|
3.76
|
4.02
|
3.98
|
|
|
126 526.43
|
224.00
|
|
3.77
|
3.90
|
3.70
|
3.70
|
3.885
|
3.88
|
|
|
36 663.56
|
172.00
|
|
3.72
|
4.00
|
3.6601
|
3.66
|
3.7899
|
3.7899
|
|
|
108 977.58
|
137.00
|
|
3.65
|
3.92
|
3.76
|
3.68
|
3.90
|
3.795
|
|
|
58 366.44
|
134.00
|
|
3.65
|
3.84
|
3.68
|
3.68
|
3.8399
|
3.795
|
|
|
48 003.80
|
136.00
|
|
3.56
|
3.76
|
3.66
|
3.66
|
3.8776
|
3.70
|
|
|
37 572.84
|
108.00
|
|
3.44
|
4.10
|
3.80
|
3.71
|
3.90
|
3.71
|
|
|
133 674.40
|
600.00
|
Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis.
GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.
Показать все Скрыть